Table 2.
Comparative activity of oxazolidinones against Staphylococcus aureus with identified mechanisms of reduced susceptibility [29, 34, 36, 57]
| Mechanism (n) | Number of isolates with MIC (% inhibited at specified concentration) | Susceptible (%) | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| 0.5 | 1 | 2 | 4 | 8 | 16 | 32 | 64 | 128 | ||
| 23S rRNA mutations (17) | ||||||||||
| Tedizolid | – | 1 (6) | 9 (59) | 4 (82) | 2(94) | 1 (100) | – | – | – | 0 |
| Linezolid | – | – | – | 1 (6) | 1(12) | 7 (53) | 4 (77) | 4 (100) | – | 0 |
| L3 or L4 modifications (6) | ||||||||||
| Tedizolid | 1 (17) | 2 (50) | 3 (100) | – | – | – | – | – | – | 17 |
| Linezolid | – | – | 1 (17) | 1 (33) | 4(100) | – | – | – | – | 0 |
| cfr positive (13) | ||||||||||
| Tedizolid | 11 (85) | 2 (100) | – | – | – | – | – | – | – | 85 |
| Linezolid | – | – | – | – | 3(23) | 9 (92) | 1 (100) | – | – | 0 |
| Multiple mechanisms (5) | ||||||||||
| Tedizolid | – | 2 (40) | 3 (100) | – | – | – | – | – | – | 0 |
| Linezolid | – | – | – | – | – | – | 2 (40) | 3 (100) | – | 0 |